Retinopathy News and Research

RSS

Research with UWF imaging may change how diabetic eye disease is assessed and treated

For decades, clinicians have detected and monitored diabetic eye disease with standard retinal photographs that cover about a third of the retina. In recent years, an emerging class of ultrawide field (UWF) cameras has given a substantially larger view of the retina, providing new insight on the presentation and natural history of retinal disease.

28 Aug 2015

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

A team of researchers in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy (a murine model used to mimic eye disease).

20 Aug 2015

Sigma 1 receptor appears to play vital role in supporting the retina

A receptor that is already a target for treating neurodegenerative disease also appears to play a key role in supporting the retina, scientists report.

11 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

For two decades beginning in the late 1970’s through 2001, clinicians relied upon laser photocoagulation in the treatment of wet AMD caused by choroidal neovascularization. Attempts to obliterate the neovascular lesions often led to acute central visual loss and often, even with modest success, the lesions recurred with even more vision loss.

21 Jul 2015

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd., announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd.

14 Jul 2015

Retinal function, structure changes in proliferative diabetic retinopathy revealed

Patients with proliferative diabetic retinopathy exhibit marked visual dysfunction and structural changes in both the inner and outer retinal layers, research findings indicate.

8 Jul 2015

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Progression and severity of macular atrophy are the main anatomical determinants of long-term visual outcomes in exudative age-related macular degeneration patients treated with ranibizumab, suggest SEVEN-UP study results.

8 Jul 2015

Darapladib shows promise in diabetic macular oedema

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation.

8 Jul 2015

Vitrectomy scatter photocoagulation linked to peripheral thickening in diabetic retinopathy

Early transient peripheral retinochoroidal thickening following pars plana vitrectomy for proliferative diabetic retinopathy may be related to intraoperative scatter photocoagulation, suggest researchers.

30 Jun 2015

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker.

30 Jun 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

Researchers advance stem cell therapy to block vision loss caused by diabetic retinopathy

University of Virginia School of Medicine researchers have taken a significant step forward in their efforts to use stem cells to block vision loss caused by diabetic retinopathy, a condition that affects millions of people with diabetes.

25 Jun 2015

Innovative formula prevents risks, painful treatments in people with secondary blindness

The Mexican company "Medical and Surgical Center for Retina" created a way to transport drugs, in order to avoid risks and painful treatments in people with secondary blindness due to chronic degenerative blindness such as diabetic retinopathy and degeneration of the eye.

25 Jun 2015

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. in a stock-for-stock transaction.

19 Jun 2015

JAMA: Extremely preterm infants enrolled in randomized clinical trials experience neither better nor worse outcomes

In a group of more than 5,000 extremely preterm infants, important in-hospital outcomes were neither better nor worse in infants enrolled in randomized clinical trials (RCTs) compared with eligible but nonenrolled infants, findings that may provide reassurance regarding concerns about performing RCTs in this vulnerable population, according to a study in the June 16 issue of JAMA.

17 Jun 2015

Leica Microsystems to acquire OCT company Bioptigen

Bioptigen develops and manufactures innovative OCT systems and software and is globally successful with products for clinical as well as translational research applications. Using low-power, near-infrared light, Bioptigen OCTs generate high-resolution, volumetric images of the eye...

From Leica Microsystems GmbH 2 Jun 2015

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Retinopathy News and Research

Research with UWF imaging may change how diabetic eye disease is assessed and treated

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

Sigma 1 receptor appears to play vital role in supporting the retina

Shire acquires Foresight Biotherapeutics for $300 million

3SBio purchases entire equity interest in Zhejiang Wansheng

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

Retinal function, structure changes in proliferative diabetic retinopathy revealed

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Darapladib shows promise in diabetic macular oedema

Vitrectomy scatter photocoagulation linked to peripheral thickening in diabetic retinopathy

ORT incidence increases in nAMD despite anti-VEGF treatment

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Researchers advance stem cell therapy to block vision loss caused by diabetic retinopathy

Innovative formula prevents risks, painful treatments in people with secondary blindness

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

JAMA: Extremely preterm infants enrolled in randomized clinical trials experience neither better nor worse outcomes

Leica Microsystems to acquire OCT company Bioptigen

Medicare physician reimbursement data could be confusing to the public

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News